Mr. Batchelder’s most recent operational role was as co–founder and CEO of Civitas Therapeutics (acquired by Acorda Therapeutics). Prior to Civitas he served as CEO of BIND Therapeutics (acquired by Pfizer) and Acceleron Pharma (acquired by Merck). He started his biotechnology career at Millennium Pharmaceutical serving in roles of increasing responsibility including SVP of Operations and where he played a leadership role in the launch of VELCADE® and was responsible for the commercial supply chain and technical operations for INTEGRLIN®. During his more than 30 years of executive leadership experience he also served in functional roles including operations, sales, marketing, business development, manufacturing, supply chain management and R&D. Mr. Batchelder currently serves as Executive Chair of XyloCor Therapeutics and Synchronicity Pharma. He also serves on the board of OncXerna and the Michael J. Fox Foundation for Parkinson’s Research. He was formerly chairman of MassBio. He received a BS in Chemical Engineering from Lehigh University.
Venture Partner – Pivotal bioVenture Partners (US)